Multi-source·Jul 23, 2026·3 sources analyzed
FTC opened comments on a Caremark insulin-pricing settlement
The Federal Trade Commission accepted a proposed consent order with CVS Caremark in its insulin PBM case, giving the public 30 days to comment before the order can become final. (sources: www.ftc.gov)
Image: Modern Action subject: Prescription drug prices
Modern Action Briefing
The FTC is currently reviewing comments on a settlement agreement with Caremark concerning insulin pricing. The case remains pending as the agency evaluates public input.
- The FTC has an administrative case involving Caremark and insulin pricing.
- A settlement agreement was reached on July 14.
- The case is still pending as the FTC collects comments.
Why it matters
The outcome of this case could impact insulin pricing practices and access to medications.
Connected public decisions
Follow the issue pages where this story connects to public action.
Contact officials
Act on Prescription drug prices
See the current decision, choose your position, and send a message through the issue page.
Take action on Prescription drug prices